Answers are grounded in this paper and cite their sources.
PROLOGUE: When Congress tackles the tough issues surrounding whether to add outpatient prescription drugs to Medicare's benefit package, legislators will be forced to address similar questions that have vexed the program for years. Who should administer the benefit? Who should be eligible? How broad should the benefit be? And who should pay? Perhaps the most controversial of these issues is how payment should be apportioned in society. It was this very issue that brought repeal of the Medicare Catastrophic Coverage Act of 1988 when Congress differentiated the Medicare Part B premium on the basis of a beneficiary's income. In this paper the authors explore these questions and more, asserting along the way that the major prescription drug benefit proposals already introduced in Congress “may not be far apart.” McClellan is a professor of economics and medicine at Stanford University. During a sabbatical year (1998–1999), McClellan served as deputy assistant secretary for economic policy for the U.S. Department of the Treasury, where he helped to develop economic policy on a range of domestic issues including Medicare reform. Ian Spatz is senior director and counsel for Merck and Company in Washington, D.C. Spatz is responsible for policy development and representation for Merck on issues including national health care policies; pharmaceutical pricing; intellectual property protection; and federal regulation of the research, approval, manufacturing, and marketing of medicines. Stacie Carney is a research analyst at the National Bureau of Economic Research in Stanford, California, and a graduate of Stanford University. ABSTRACT: We review the policy concerns underlying some of the most contentious issues that must be resolved prior to the enactment of a Medicare drug benefit. We consider critical issues both in benefit design—targeted versus universal eligibility, benefit subsidies, and benefit comprehensiveness—and in benefit administration, focusing especially on issues involving the administration of the drug benefit in traditional Medicare. Despite the apparent contentiousness of the drug benefit debate, alternative proposals may not be so far apart on these issues.
No takes yet. Share an insight, caveat, or question.
McClellan et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: